Literature DB >> 3125357

Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles.

K Iriyama1, H Nishiwaki, H Terashima, H Tonouchi, C Miki, H Suzuki, Y A Carpentier.   

Abstract

Artificial lipid particles used as parenteral nutrition solution do not contain any apolipoproteins when they are infused into the circulation. Despite the absence of apolipoproteins, the metabolism of artificial lipid particles is similar to that of chylomicrons which contain various kinds of apolipoprotein. Of the known apolipoproteins, apolipoprotein C-II (apo C-II) is important in the hydrolysis of triglyceride-rich lipoproteins via involvement in the activation of lipoprotein lipase. Modifications of apo C-II associated with intravenous infusion of a lipid emulsion were investigated in eight patients. Changes in apo C-IIs in high density lipoproteins (HDL), low density lipoproteins (LDL) and very low density lipoproteins (VLDL) together with the plasma level of triglycerides, were quantified before and for 90 min after a bolus injection of a 10% lipid emulsion (1 ml/kg of body weight). Immediately prior to the injection, 54% of the total amount of apo C-II was present in HDL, while 27% was present in VLDL. After 5 to 10 min, the amount of apo C-II in HDL decreased to 29% of the total, while that in VLDL increased to 62%. Subsequently, the amounts of apo C-II in HDL and VLDL began to return to the preinjection levels. These variations in apo C-II were closely correlated with the plasma clearance of triglyceride. The result indicates that the injected lipids are not inert particles during their short intravascular life, but that they acquire apo C-II from HDL.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3125357     DOI: 10.1177/014860718801200160

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  3 in total

Review 1.  The metabolic distinctiveness of emulsified lipid particles in the bloodstream and its clinical implications.

Authors:  K Iriyama
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

2.  Biomarkers for late-onset neonatal sepsis.

Authors:  Richard A Polin; Tara M Randis
Journal:  Genome Med       Date:  2010-09-06       Impact factor: 11.117

3.  Intravenous niacin acutely improves the efficiency of dietary fat storage in lean and obese humans.

Authors:  Robert H Nelson; Danielle Vlazny; Almira Smailovic; John M Miles
Journal:  Diabetes       Date:  2012-08-24       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.